Constantine Mitsiades

3.8k total citations · 1 hit paper
31 papers, 2.6k citations indexed

About

Constantine Mitsiades is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Constantine Mitsiades has authored 31 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 17 papers in Oncology and 13 papers in Hematology. Recurrent topics in Constantine Mitsiades's work include Multiple Myeloma Research and Treatments (12 papers), Peptidase Inhibition and Analysis (11 papers) and Ubiquitin and proteasome pathways (9 papers). Constantine Mitsiades is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Peptidase Inhibition and Analysis (11 papers) and Ubiquitin and proteasome pathways (9 papers). Constantine Mitsiades collaborates with scholars based in United States, Greece and Switzerland. Constantine Mitsiades's co-authors include Kenneth C. Anderson, Paul G. Richardson, Nicholas Mitsiades, Nikhil C. Munshi, Teru Hideshima, Dharminder Chauhan, Vassiliki Poulaki, Xuesong Gu, Steven P. Treon and Towia A. Libermann and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Constantine Mitsiades

31 papers receiving 2.5k citations

Hit Papers

Molecular sequelae of proteasome inhibition in human mult... 2002 2026 2010 2018 2002 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Molecular sequelae of proteasome inhibition in human multiple myeloma cells
    2002 597 citations Nicholas Mitsiades, Constantine Mitsiades et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Constantine Mitsiades United States 20 2.1k 1.2k 899 255 250 31 2.6k
Manik Chatterjee Germany 32 1.7k 0.8× 880 0.7× 844 0.9× 424 1.7× 246 1.0× 87 2.7k
Emanuela Colombo Italy 23 2.1k 1.0× 980 0.8× 545 0.6× 253 1.0× 151 0.6× 37 2.7k
W. Michael Kuehl United States 14 2.1k 1.0× 1.2k 1.0× 624 0.7× 322 1.3× 166 0.7× 21 2.7k
Jiro Kikuchi Japan 27 1.5k 0.7× 685 0.6× 594 0.7× 352 1.4× 138 0.6× 89 2.2k
Sophie Barillé‐Nion France 27 1.4k 0.7× 918 0.8× 1.3k 1.4× 359 1.4× 113 0.5× 59 2.5k
Chie Nishioka Japan 29 1.1k 0.5× 718 0.6× 509 0.6× 354 1.4× 429 1.7× 63 2.1k
Fausto Grignani Italy 20 3.0k 1.4× 1.2k 1.0× 677 0.8× 508 2.0× 203 0.8× 50 3.8k
Rekha Rao United States 25 1.8k 0.8× 506 0.4× 401 0.4× 170 0.7× 238 1.0× 49 2.2k
Wendy Schober United States 34 1.8k 0.9× 751 0.6× 729 0.8× 663 2.6× 142 0.6× 64 3.0k
J I Johnson United States 7 1.3k 0.6× 359 0.3× 853 0.9× 138 0.5× 187 0.7× 7 2.0k

Countries citing papers authored by Constantine Mitsiades

Since Specialization
Citations

This map shows the geographic impact of Constantine Mitsiades's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Constantine Mitsiades with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Constantine Mitsiades more than expected).

Fields of papers citing papers by Constantine Mitsiades

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Constantine Mitsiades. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Constantine Mitsiades. The network helps show where Constantine Mitsiades may publish in the future.

Co-authorship network of co-authors of Constantine Mitsiades

This figure shows the co-authorship network connecting the top 25 collaborators of Constantine Mitsiades. A scholar is included among the top collaborators of Constantine Mitsiades based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Constantine Mitsiades. Constantine Mitsiades is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Richardson, Paul G., Jacob P. Laubach, Robert Schlossman, et al.. (2012). The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. European Journal Of Haematology. 88(5). 446–449. 8 indexed citations
2.
Laubach, Jacob P., Robert Schlossman, Constantine Mitsiades, Kenneth C. Anderson, & Paul G. Richardson. (2011). Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Review of Hematology. 4(1). 51–60. 19 indexed citations
3.
Richardson, Paul G., Constantine Mitsiades, Jacob P. Laubach, et al.. (2011). Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. British Journal of Haematology. 152(4). 367–379. 112 indexed citations
4.
Siegel, David, Sundar Jagannath, David H. Vesole, et al.. (2011). A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leukemia & lymphoma. 52(12). 2308–2315. 23 indexed citations
5.
Richardson, Paul G., Jacob P. Laubach, Constantine Mitsiades, et al.. (2011). Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. British Journal of Haematology. 154(6). 755–762. 13 indexed citations
6.
Dimopoulos, Meletios Α., Constantine Mitsiades, Kenneth C. Anderson, & Paul G. Richardson. (2011). Tanespimycin as Antitumor Therapy. Clinical Lymphoma Myeloma & Leukemia. 11(1). 17–22. 35 indexed citations
7.
Richardson, Paul G., Jacob P. Laubach, Anuj Mahindra, et al.. (2010). THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT. Mediterranean Journal of Hematology and Infectious Diseases. 2(2). e2010009–e2010009. 3 indexed citations
8.
Mitsiades, Constantine & Kenneth C. Anderson. (2009). Epigenetic Modulation in Hematologic Malignancies: Challenges and Progress. Journal of the National Comprehensive Cancer Network. 7(Suppl 8). S–1. 5 indexed citations
9.
Richardson, Paul G., Constantine Mitsiades, Kathleen Colson, et al.. (2008). Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia & lymphoma. 49(3). 502–507. 167 indexed citations
10.
Sukhdeo, Kumar, Mala Mani, Yunyu Zhang, et al.. (2007). Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proceedings of the National Academy of Sciences. 104(18). 7516–7521. 184 indexed citations
11.
Mitsiades, Constantine, Nicholas Mitsiades, Nikhil C. Munshi, Paul G. Richardson, & Kenneth C. Anderson. (2006). The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. European Journal of Cancer. 42(11). 1564–1573. 164 indexed citations
12.
Mitsiades, Constantine, Nicholas Mitsiades, Teru Hideshima, Paul G. Richardson, & Kenneth C. Anderson. (2005). Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Review of Anticancer Therapy. 5(3). 465–476. 13 indexed citations
13.
Hideshima, Teru, Klaus Podar, Dharminder Chauhan, et al.. (2004). p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 23(54). 8766–8776. 105 indexed citations
14.
Mitsiades, Constantine, Nicholas Mitsiades, Joseph Negri, et al.. (2004). IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.. Blood. 104(11). 2403–2403. 6 indexed citations
15.
Hideshima, Teru, Dharminder Chauhan, Toshiaki Hayashi, et al.. (2003). Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.. PubMed. 63(23). 8428–36. 58 indexed citations
16.
Chauhan, Dharminder, Guilan Li, Teru Hideshima, et al.. (2003). Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 102(9). 3379–3386. 124 indexed citations
17.
Poulaki, Vassiliki, Constantine Mitsiades, Vassiliki Kotoula, et al.. (2002). Regulation of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Thyroid Carcinoma Cells. American Journal Of Pathology. 161(2). 643–654. 59 indexed citations
18.
LeBlanc, Richard, Laurence Catley, Teru Hideshima, et al.. (2002). Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.. PubMed. 62(17). 4996–5000. 372 indexed citations
19.
Mitsiades, Nicholas, et al.. (2001). Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug. Expert Opinion on Investigational Drugs. 10(6). 1075–1084. 19 indexed citations
20.
Koutsilieris, Michael, et al.. (2001). A Combination Therapy of Dexamethasone and Somatostatin Analog Reintroduces Objective Clinical Responses to LHRH Analog in Androgen Ablation-Refractory Prostate Cancer Patients. The Journal of Clinical Endocrinology & Metabolism. 86(12). 5729–5736. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manik Chatterjee Breakdown of academic impact, for papers by Emanuela Colombo Breakdown of academic impact, for papers by W. Michael Kuehl Breakdown of academic impact, for papers by Jiro Kikuchi Breakdown of academic impact, for papers by Sophie Barillé‐Nion Breakdown of academic impact, for papers by Chie Nishioka Breakdown of academic impact, for papers by Fausto Grignani Breakdown of academic impact, for papers by Rekha Rao Breakdown of academic impact, for papers by Wendy Schober Breakdown of academic impact, for papers by J I Johnson
Rankless by CCL
2026